Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 4, 1999

View Archived Issues

Company Profile: Metabolic Pharmaceuticals

Anticancer immunotoxin available for licensing from NIH

Antimalarial alkaloid compounds available for licensing from NIH

New anti-HIV compound progresses in clinical studies at BMS

Triangle initiates phase II/III testing of FTC in HIV and HBV infections

New treatment for AIDS-related pain progresses to clinical testing

12-HETE inhibitor suppresses coronary thrombosis in dog model

Novel compounds synthesized at SmithKline Beecham act at several 5-HT receptor subtypes

New COX-2 inhibitor series patented by Searle

Thrombin inhibitors in development at Lilly

Lilly's new 5-HT1D agonists claimed for CNS and bladder disorders

Warner-Lambert claims new kappa-opioid agonists and their use

Expanded use of Photofrin approved by FDA

Prometrium cleared for U.S. marketing for HRT

Telomerase expression extends lifespan of normal human cells without oncogenic transformation

New research agreement to advance development of Medical Discoveries' novel AIDS drug

Important end-of-year approval by FDA: Celebrex for arthritis

Oligo- and polyribonucleotides with anti-HIV and anti-HCMV activity

Selective inhibitor of neuronal dopamine transporter developed by U.S. university team

Physician recommendations for Viagra use issued

Antiulcer effects and mechanism of action of AU-006 explored

MCC-555 improves metabolic status, insulin sensitivity in diabetic and obese rat models

Potent antimalarial activity demonstrated for diterpenoid produced by Okinawan sponge

ACE inhibitor trandolapril improves peripheral neuropathy in normotensive diabetic patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...